Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct;19(10):627.
doi: 10.1038/s41585-022-00623-z.

Androgen receptor pathway inhibitor combination in prostate cancer

Kelvin Yan  1
Affiliations
Comment

Androgen receptor pathway inhibitor combination in prostate cancer

Kelvin Yan. Nat Rev Urol. 2022 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Fenner, A. Darolutamide combo is an ARASENSible option for mHSPC. Nat. Rev. Urol. https://doi.org/10.1038/s41585-022-00579-0 (2022). - DOI - PubMed - PMC
    1. Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2119115 (2022). - DOI - PubMed - PMC
    1. Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019). - DOI
    1. Fizazi, K. et al. A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1 [abstract LBA5_PR]. Ann. Oncol. 32 (Suppl. 5), S1283–S1346 (2021).
    1. Wenzel, M. et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-021-00395-4 (2022). - DOI - PubMed

LinkOut - more resources